Highlights CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H3003

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
1.84 ^USD	-35.21%		-23.97%	-97.10%

06-26	Top Midday Decliners	MT
06-26	Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Top Midday Decliners	06-26	MT
Sector Update: Health Care Stocks Advance Late Afternoon	06-10	MT
CNS Pharmaceuticals Files Registration Statement for $9.2 Million Share, Warrant Offering -- Shares Fall	06-10	MT
CNS Pharmaceuticals Schedules 1-For-50 Reverse Stock Split This Week	06-03	MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings	01-30	MT
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	01-17	CI
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin	12-18	CI
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy	11-22	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland	23-10-11	CI
Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme	23-09-07	CI
CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy	23-08-14	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme	23-08-03	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
CNS Pharmaceuticals, Inc. Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of Gbm with First Patient Enrolled in Switzerland	23-03-09	CI
Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug	23-02-24	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H3003

Highlights

Filters